News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO): Tresiba(R) (Insulin Degludec) And Ryzodeg(R) (Insulin Degludec/Insulin Aspart) Receive Positive Opinions From the European Regulatory Authorities



10/19/2012 9:49:54 AM

BAGSVAERD, DENMARK--(Marketwire - October 19, 2012) -


Company Announcement No 66 / 2012: http://hugin.info/2013/R/1650358/532183.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i)  the releases contained herein are protected by copyright and
     other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE [HUG#1650358]


Further information:

Media:
Mike Rulis
Tel: (+45) 3079 3573
Email Contact

Investors:

Kasper Roseeuw Poulsen
Tel: (+45) 4442 4303
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

In North America:

Ambre Morley
Tel: (+1) 609 216 5240
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES